Search research articles
Contact Us
Filters
Showing results (1031-1040 of 1,834) with videos related to
Page
of 184
Sort By:
Mabs
|
December 8, 2022
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies
Andrew Dippel, Austin Gallegos, Vineela Aleti, et al.
Mabs
|
November 23, 2022
A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers
James T Heads, Sebastian Kelm, Kerry Tyson, et al.
Mabs
|
November 27, 2019
Heparin chromatography as an <i>in vitro</i> predictor for antibody clearance rate through pinocytosis
Thomas E Kraft, Wolfgang F Richter, Thomas Emrich, et al.
Mabs
|
November 29, 2019
Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences
Gargi Roy, Jason Reier, Andrew Garcia, et al.
Mabs
|
July 22, 2021
Targeting cancer with antibody-drug conjugates: Promises and challenges
Alexis Q Dean, Shen Luo, Julianne D Twomey, et al.
Mabs
|
December 15, 2020
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
Marco Tuccori, Sara Ferraro, Irma Convertino, et al.
Mabs
|
July 27, 2021
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV
Wen Jiang, Junchao Wang, Shasha Jiao, et al.
Mabs
|
July 27, 2021
Highly sensitive detection of antibody nonspecific interactions using flow cytometry
Emily K Makowski, Lina Wu, Alec A Desai, et al.
Mabs
|
March 16, 2013
Response to: monoclonal antibodies targeting CD20
Christian Klein, Alfred Lammens, Wolfgang Schäfer, et al.
Mabs
|
April 4, 2013
Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn
Matthew J Bernett, Seung Y Chu, Irene Leung, et al.
Page
of 184
Search research articles
Search
Showing results (1031-1040 of 1,834) with videos related to
Sort By:
Page
of 184
Mabs
|
December 8, 2022
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies
Andrew Dippel, Austin Gallegos, Vineela Aleti, et al.
Mabs
|
November 23, 2022
A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers
James T Heads, Sebastian Kelm, Kerry Tyson, et al.
Mabs
|
November 27, 2019
Heparin chromatography as an <i>in vitro</i> predictor for antibody clearance rate through pinocytosis
Thomas E Kraft, Wolfgang F Richter, Thomas Emrich, et al.
Mabs
|
November 29, 2019
Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences
Gargi Roy, Jason Reier, Andrew Garcia, et al.
Mabs
|
July 22, 2021
Targeting cancer with antibody-drug conjugates: Promises and challenges
Alexis Q Dean, Shen Luo, Julianne D Twomey, et al.
Mabs
|
December 15, 2020
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
Marco Tuccori, Sara Ferraro, Irma Convertino, et al.
Mabs
|
July 27, 2021
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV
Wen Jiang, Junchao Wang, Shasha Jiao, et al.
Mabs
|
July 27, 2021
Highly sensitive detection of antibody nonspecific interactions using flow cytometry
Emily K Makowski, Lina Wu, Alec A Desai, et al.
Mabs
|
March 16, 2013
Response to: monoclonal antibodies targeting CD20
Christian Klein, Alfred Lammens, Wolfgang Schäfer, et al.
Mabs
|
April 4, 2013
Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn
Matthew J Bernett, Seung Y Chu, Irene Leung, et al.
Page
of 184